News

Latest News
Dec 2, 2019

Mylan N.V. (NASDAQ: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced the U.S. launch of Ogivri™ (trastuzumab-dkst), a biosimilar to Herceptin® (trastuzumab). Ogivri is...

Nov 25, 2019

Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that it will present at the Evercore ISI HealthCONx Conference in Boston on Tuesday, Dec. 3, 2019 at 11 a.m. ET. Interested...

Nov 20, 2019

On November 20, 2019, Mylan N.V. delivered a notice to The Bank of New York Mellon, as trustee (the “Trustee”), notifying the Trustee of its election to redeem (the “Partial Redemption”),...

Nov 12, 2019

Nov. 12, 2019 The U.S. Food and Drug Administration (FDA) issued a Warning Letter to Mylan’s API manufacturer, Mylan Laboratories Limited Unit 8, on November 5, 2019. The concerns cited by the...

Nov 12, 2019

Mylan N.V. (NASDAQ: MYL) and Pfizer Inc. (NYSE: PFE) today announced that the name of the new company to be formed by the planned combination of Mylan and Upjohn, a division of Pfizer, will be...

View More

Search News Releases
Contact Mylan Communications

Global Communications 
724.514.1968
communications@mylan.com

Stay Connected

Mylan: Seeing is Believing

You are leaving Mylan.com

By clicking Continue below you are leaving Mylan.com and going to a third-party site.